Company Overview and News

 
Admission to Trading on AIM

2017-08-08 londonstockexchange
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW.

 
IDT Corporation to Report Third Quarter Fiscal Year 2017 Results

2017-05-26 prnewswire
NEWARK, N.J., May 26, 2017 /PRNewswire/ -- IDT Corporation (NYSE: IDT), a global provider of communications and payment services, has scheduled its report of third quarter fiscal year 2017 financial and operational results for Tuesday, June 6, 2017.

 
IDW Media Holdings Names Stephen R. Brown to Board of Directors

2017-05-26 marketwired
STAMFORD, CT and SAN DIEGO, CA--(Marketwired - May 26, 2017) - IDW Media Holdings, Inc. (OTCQX: IDWM) is pleased to announce that, on May 22, 2017, Stephen R. Brown joined its Board of Directors. Since October 2016, Mr. Brown has served as the President of GMA Fund, LLC, a specialty finance company, and, since February 2015, has served as the Chief Financial Officer of Nanovibronix, Inc. (OTCBB: NAOV).

 
IDT Corporation Gained 20% in April -- But Shares Are Down in 2017

2017-05-09 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

 
Tracking Kahn Brothers Portfolio - Q1 2017 Update

2017-05-09 seekingalpha
The portfolio continues to be very concentrated, with the top five positions accounting for ~46% of the 13F holdings.

 
Golden Meditech Enters Into A Settlement Agreement With

2016-11-14 devicespace
HONG KONG, Nov. 14, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that its wholly-owned subsidiary, GM Investment Company Limited ("GM Investment"), has entered into a conditional settlement agreement with Sanpower Group Limited1 ("Sanpower") regarding an outstanding amount of approximately US$250 million owed to Fortress Group Limited ("Fortress") by Sanpower.

 
Golden Meditech Enters Into a Settlement Agreement with Sanpower

2016-11-14 prnewswire
HONG KONG, Nov. 14, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that its wholly-owned subsidiary, GM Investment Company Limited ("GM Investment"), has entered into a conditional settlement agreement with Sanpower Group Limited1 ("Sanpower") regarding an outstanding amount of approximately US$250 million owed to Fortress Group Limited ("Fortress") by Sanpower.

 
Golden Meditech Enters Into Settlement Agreement With

2016-11-03 devicespace
HONG KONG, Nov. 3, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that its wholly-owned subsidiary, GM Investment Company Limited ("GM Investment"), has entered into a conditional settlement agreement with PAG Asia I LP and its assignee PAGAC Fortress Holding I Limited ("PAGAC") and Fortress Group Limited ("Fortress").

 
Liberty Mutual Sanpower Joint Venture

2016-08-16 londonstockexchange
Liberty Mutual Insurance Enters into Joint Venture Agreement for Its Chinese Insurance Operations with Sanpower Group Co., Ltd., one of China's Leading Private Enterprises

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...